Meropenem Olikla (Meropenem Anhydrous)

Meropenem is a broad‑spectrum carbapenem used for serious bacterial infections that require intravenous therapy.

• Complicated intra‑abdominal infections: provides bactericidal activity against polymicrobial pathogens to resolve infection.
• Hospital‑acquired pneumonia: targets resistant Gram‑negative and Gram‑positive organisms to improve lung infection outcomes.
• Ventilator‑associated pneumonia: eliminates causative bacteria, aiding recovery in ventilated patients.
• Complicated urinary tract infections: eradicates resistant uropathogens, facilitating urinary system healing.
• Severe sepsis and septic shock: rapidly reduces bacterial load, supporting hemodynamic stabilization.
• Meningitis caused by susceptible organisms: penetrates the cerebrospinal fluid to treat central nervous system infections.

• Meropenem inhibits bacterial cell wall synthesis by binding with high affinity to penicillin‑binding proteins (PBPs). This binding disrupts the final transpeptidation step of peptidoglycan cross‑linking, leading to loss of cell wall integrity and bacterial lysis. The drug exhibits broad activity against Gram‑negative, Gram‑positive, and anaerobic organisms, including many resistant strains, resulting in a rapid bactericidal effect.

Adverse reactions may occur with meropenem therapy and are categorized by frequency.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: may be watery and self‑limiting.
• Rash: skin erythema or pruritus.
• Headache: transient cranial discomfort.
• Elevated liver enzymes: mild transaminase increase.
• Injection site reactions: pain, erythema, or swelling at the infusion site.

Serious or Rare Side Effects

• Clostridioides difficile‑associated diarrhea: severe colitis requiring medical attention.
• Anaphylaxis: acute hypersensitivity with respiratory or circulatory compromise.
• Seizures: particularly in patients with CNS disorders or renal impairment.
• Renal toxicity: worsening kidney function in susceptible individuals.
• Severe allergic reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Thrombophlebitis: inflammation of veins at the infusion site.

Careful assessment and monitoring are essential when using meropenem.

• Assess renal function: adjust dosing in patients with impaired clearance.
• Monitor for hypersensitivity: discontinue if signs of allergic reaction appear.
• Adjust dose in renal impairment: follow prescriber guidance for reduced dosing.
• Use caution in CNS disorders: increased risk of seizures.
• Avoid concomitant use with valproic acid: may lower valproate levels and precipitate seizures.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Valproic acid: meropenem reduces serum valproate concentrations, risking seizure breakthrough.
• Probenecid: may increase meropenem plasma levels, enhancing toxicity.
• Carbapenem‑induced reduction of oral contraceptives: may diminish contraceptive effectiveness.

Moderate Interactions (Monitor Closely)

• Nephrotoxic agents (e.g., aminoglycosides, vancomycin): combined use may worsen renal function.
• Anticoagulants (e.g., warfarin): monitor INR for potential alterations.
• Loop diuretics: may affect electrolyte balance; observe patient status.